# Collegium Pharmaceutical Inc. (COLL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $23.53, market value $729 million.

## Valuation
- **P/E (trailing): 18.5×** (5-yr avg 19.0×, 3-yr avg 22.0×). Collegium Pharmaceutical Inc. trades at 18.5× trailing earnings, close to its own five-year average of 19.0×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 3.5×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.9×**. Each dollar of revenue is priced at 0.9×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 45.0%** (5-yr avg 17.1%). Free cash flow equals 45.0% of the market value, above its five-year average of 17.1%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 5.4%**. The inverse of the P/E: 5.4% of the price is earned each year.

## Profitability
- **Gross margin: 60.0%**. Collegium Pharmaceutical Inc. keeps 60.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 19.5%**. 19.5% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 8.1%**. 8.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 20.8%**. 20.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 151.8%**. Return on all capital, debt included, is 151.8%: comfortably above what that capital costs.
- **Return on assets: 2.9%**. Each dollar of assets produces 2.9% of profit.

## Growth
- **Revenue growth (1 yr): 23.6%** (3-yr 18.9%/yr, 5-yr 20.3%/yr). Revenue grew 23.6% over the last year, against 20.3% a year compounded over five years.
- **EPS growth (1 yr): -7.0%** (5-yr 17.9%/yr). Earnings per share fell 7.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 38.8%/yr**. Free cash flow has compounded at 38.8% a year over three years.

## Financial health
- **Debt to equity: 0.04**. Debt is 0.04 times equity: a conservative balance sheet.
- **Current ratio: 1.57** (quick 1.57). Current assets cover the next year's liabilities 1.57 times.
- **Altman Z-score: 1.59**. A Z-score of 1.59 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Collegium Pharmaceutical Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Collegium Pharmaceutical Inc.; the consensus is buy, with an average price target of $49.60 (+111% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -40.0%** (YTD -49.2%, 3-mo -29.5%). The shares are down 40.0% over twelve months including dividends.
- **From 52-week high: -53.7%** (0.7% above the low). Trading 54% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 24**. An RSI of 24 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 0.37** (volatility 45%). Beta of 0.37 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=COLL · Page: https://foliofundamentals.com/stocks/coll

Not investment advice.